Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01192594 · ClinicalTrials.gov registry record · Phase 3
Milestones of Adjustment Post-Psychosis
A Phase 3 study, sponsored by Yale University.
- Terminated
- Registry status
- Phase 3
- Development phase
- 110
- Enrollment target
NCT01192594 is a Phase 3 study that was terminated before completion, run by Yale University. The registered enrollment target is 110 participants.
The verdict
NCT01192594, a Phase 3 study, was terminated before completion, sponsored by Yale University.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 110 participants
- Enrollment target
Study Summary
This nested design clinical outcome study of psychiatric case manager education on disease state, psychopharmacology of schizophrenia, relapse, motivational interviewing, and the process of psychological adjustment post-psychosis (Milestones of Adjustment Post-Psychosis Recovery Model-MAPP) will test the following hypotheses: 1. Medication non-adherence in patients with schizophrenia assigned to case managers who receive MAPP training will decrease from their pre-study rate and from the reported national average after one year enrollment compared to consumers not enrolled in the MAPP arm of the study. 2. Consumers in the MAPP intervention will have higher Quality of Life Enjoyment and Satisfaction Questionnaire (Q-Les-Q (53) scores than consumers not enrolled in the MAPP at quarterly measures. 3. Consumers enrolled in the MAPP intervention arm of the study will successfully complete the first two phases of the MAPP Recovery Model in one year. 4. Consumers in the MAPP intervention arm will have greater symptom reductions at quarterly data points compared to consumers not enrolled in the MAPP intervention arm.
Interventions
- BEHAVIORAL Training in all modules including MAPP Recovery Model
- BEHAVIORAL Training in all modules except MAPP Recovery Model
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2009-11 |
| Est. Completion | 2013-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01192594
The ClinicalTrials.gov registry entry for NCT01192594 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Training in all modules including MAPP Recovery Model is the first listed.
NCT01192594 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01192594 about?
NCT01192594 is a clinical study titled "Milestones of Adjustment Post-Psychosis". This nested design clinical outcome study of psychiatric case manager education on disease state, psychopharmacology of schizophrenia, relapse, motivational interviewing, and the process of psychological adjustment post-psychosis (Milestones of Adjustment Post-Psychosis Recovery Model-MAPP) will tes...
What is the current status of trial NCT01192594?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 110 participants. The study started on 2009-11. Estimated completion is 2013-01.
What interventions are being tested in trial NCT01192594?
The interventions under investigation include: Training in all modules including MAPP Recovery Model (BEHAVIORAL), Training in all modules except MAPP Recovery Model (BEHAVIORAL).
Who is sponsoring clinical trial NCT01192594?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.